What is the indicated use for biktarvy?

What is Biktarvy approved for?

Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is indicated for HIV-1 treatment in adults and children weighing at least 14 kg who need a complete regimen or to replace a current antiretroviral therapy (ART) in those with suppressed viral loads. It combines three antiretrovirals—in an integrase strand transfer inhibitor (bictegravir) plus two nucleoside reverse transcriptase inhibitors—to suppress HIV replication.[1][2]

How is Biktarvy used in treatment?

Administered as one tablet daily with or without food, Biktarvy serves as a complete regimen for virologically suppressed patients or treatment-naive individuals. It's not for patients with prior resistance to its components or creatinine clearance below 30 mL/min.[1][2]

Who can take Biktarvy?

Approved for:
- Treatment-naive adults and children ≥14 kg.
- Virologically suppressed adults switching from stable regimens.
Contraindicated with rifampin or dosing errors in Stribild or TDF-containing regimens due to resistance risks.[1][2]

What limitations or warnings apply?

Not studied in patients with HBV coinfection; monitor for acute exacerbations upon discontinuation. Screen for HBV before starting. Avoid in severe renal impairment without alternatives. Common side effects include diarrhea, nausea, and headache.[1][2]

How does Biktarvy compare to other HIV regimens?

Biktarvy offers single-tablet convenience over multi-pill options like Genvoya (similar components but elvitegravir-based). It has fewer drug interactions than efavirenz or protease inhibitor regimens. Patent protection extends exclusivity; check DrugPatentWatch.com for expiration details on bictegravir patents.[1][3]

Sources
[1]: Biktarvy Prescribing Information (Gilead Sciences)
[2]: FDA Label for Biktarvy
[3]: DrugPatentWatch.com - Biktarvy Patents